newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//The Manila Times
British drugmaker GSK has agreed to acquire US-listed cancer drug developer Nuvalent for $10.6 billion.
GSK will acquire Nuvalent for $10.6 billion in an all-cash deal at a 40% premium.
KEY POINTS
GSK estimates a net investment of $9.4 billion after subtracting cash acquired from Nuvalent.
The acquisition is expected to improve GSK's profit from 2027 and core earnings per share by 2029.
GSK will assume Nuvalent's existing royalty obligations to Royalty Pharma and Deerfield.
GSK aims to rapidly expand its lung cancer platform with Nuvalent's therapies and its own Ris-Rez candidate.
BRITISH drugmaker GSK on Tuesday agreed to acquire US-listed cancer drug developer Nuvalent for $10.6 billion to boost its lung cancer portfolio.
Founded in 2017, the Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies.
The all-cash deal values Nuvalent at approximately $124 per share, a 40-percent premium to its last closing price.
The acquisition provides GSK with immediate new sales growth opportunities, improving profit contributions from 2027 and a platform in lung cancer for rapid expansion with Ris-Rez, our B7-H3 targeted ADC in Phase 3 clinical development,” GSK’s CEO Luke Miels said.
Miels has been tasked with convincing investors that the drugmaker can hit a revenue target of more than 40 billion pounds by 2031, boost its drug pipeline and navigate the looming 2028 patent expiry of its HIV medicine dolutegravir.
Miels said the deal offers “significant new treatment options” for lung cancer patients and creates a platform to expand with Ris-Rez, GSK’s experimental antibody-drug conjugate in late-stage testing.
Net of cash acquired, GSK’s aggregate investment is estimated to be $9.4 billion, the British company said, adding that the deal is expected to add to sales and operating profit in 2027 and core earnings per share in 2029.
GSK will account for the transaction as a business combination and will also assume Nuvalent’s existing revenue-sharing arrangements of low-single-digit royalties payable to Royalty Pharma and Deerfield.
Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.